Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Impact of the serogroup a meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity
Clinical Infectious Diseases, Volume 56, No. 3, Year 2013
Notification
URL copied to clipboard!
Description
Background. The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of 1-29-year-olds in Burkina Faso in 2010. It is not known whether MenAfriVac has an impact on NmA carriage.Methods. We conducted a repeated cross-sectional meningococcal carriage study in a representative portion of the 1-29-year-old population in 3 districts in Burkina Faso before and up to 13 months after vaccination. One district was vaccinated in September 2010, and the other 2 were vaccinated in December 2010. We analyzed 25 521 oropharyngeal samples, of which 22 093 were obtained after vaccination.Results. In October-November 2010, NmA carriage prevalence in the unvaccinated districts was comparable to the baseline established in 2009, but absent in the vaccinated district. Serogroup X N. meningitidis (NmX) dominated in both vaccinated and unvaccinated districts. With 4 additional sampling campaigns performed throughout 2011 in the 3 districts, overall postvaccination meningococcal carriage prevalence was 6.95%, with NmX dominating but declining for each campaign (from 8.66% to 1.97%). Compared with a baseline NmA carriage prevalence of 0.39%, no NmA was identified after vaccination. Overall vaccination coverage in the population sampled was 89.7%, declining over time in 1-year-olds (from 87.1% to 26.5%), as unvaccinated infants reached 1 year of age. NmA carriage was eliminated in both the vaccinated and unvaccinated population from 3 weeks up to 13 months after mass vaccination (P =. 003).Conclusions. The disappearance of NmA carriage among both vaccinated and unvaccinated populations is consistent with a vaccine-induced herd immunity effect. © 2012 The Author 2012.
Authors & Co-Authors
Kristiansen, Paul Arne
Norway, Oslo
Universitetet I Oslo
Diomandé, Fabien V.K.
Burkina Faso, Ouagadougou
Ministere de la Sante Ouagadougou
United States, Atlanta
Centers for Disease Control and Prevention
Ba, Absatou Ky
Burkina Faso, Ouagadougou
Ministere de la Sante Ouagadougou
Sanou, Idrissa
Burkina Faso, Ouagadougou
Centre Hospitalier Universitaire Yalgado Ouedraogo
Burkina Faso, Bobo-dioulasso
Centre Hospitalier Universitaire Souro Sanou
Ouédraogo, Abdoul Salam
Burkina Faso, Bobo-dioulasso
Centre Hospitalier Universitaire Souro Sanou
Ouédraogo-Traoré, Rasmata
Burkina Faso, Ouagadougou
Ministere de la Sante Ouagadougou
Sangaré, Lassana
Burkina Faso, Ouagadougou
Centre Hospitalier Universitaire Yalgado Ouedraogo
Kandolo, Denis
Burkina Faso, Ouagadougou
Ministere de la Sante Ouagadougou
Aké, Flavien H.
Burkina Faso, Ouagadougou
Ministere de la Sante Ouagadougou
Saga, Inger Marie
Norway, Oslo
Universitetet I Oslo
Clark, Thomas A.
United States, Atlanta
Centers for Disease Control and Prevention
Misegades, Lara
United States, Atlanta
Centers for Disease Control and Prevention
Martin, Stacey W.
United States, Atlanta
Centers for Disease Control and Prevention
Thomas, Jennifer Dolan
United States, Atlanta
Centers for Disease Control and Prevention
Tiéndrebéogo, Sylvestre R.M.
Burkina Faso, Ouagadougou
Ministere de la Sante Ouagadougou
Hassan-King, Musa K.A.
France, Ferney-voltaire
Meningitis Vaccine Project
Djingarey, Mamoudou Harouna
Burkina Faso, Ouagadougou
Ministere de la Sante Ouagadougou
Messonnier, Nancy E.
United States, Atlanta
Centers for Disease Control and Prevention
Préziosi, Marie Pierre
France, Ferney-voltaire
Meningitis Vaccine Project
Switzerland, Geneva
Organisation Mondiale de la Santé
LaForce, F. Marc
France, Ferney-voltaire
Meningitis Vaccine Project
Caugant, Dominique A.
Norway, Oslo
Universitetet I Oslo
Norway, Oslo
Medisinske Fakultet
Statistics
Citations: 209
Authors: 21
Affiliations: 8
Identifiers
Doi:
10.1093/cid/cis892
ISSN:
10584838
e-ISSN:
15376591
Research Areas
Health System And Policy
Study Design
Cross Sectional Study
Study Locations
Burkina Faso